Clinical Evidence Scrutiny Matrix
Evaluate public claims, political assertions, and nominee testimony against gold-standard clinical trial designs, FDA substantial evidence mandates (21 CFR 314/601), and GRADE criteria.
Evidence Scrutiny Scorecard
3 Studies Synthesized| Study / Source | Design | Cohort N | Effect (95% CI) | FDA Tier | Action |
|---|
Senate Committee Hearing Brief & Cross-Examination Matrix
Scrutiny Finding: The scrutinized assertion is directly supported by multi-center randomized controlled trials meeting FDA statutory requirements.
Statutory Standards for Regulatory Evidence
Under Section 505(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), regulatory approval requires "substantial evidence" consisting of adequate and well-controlled investigations by qualified scientific experts.
When public officials or nominees advocate policy positions or question vaccine and therapeutic efficacy, congressional committees cross-examine testimony against:
- Adequate and Well-Controlled Studies (21 CFR 314.126): Randomization, double-blinding, protocol-specified endpoints, and predefined statistical analysis plans.
- Observational Real-World Evidence (RWE): Susceptible to confounding, selection bias, and immortal time bias unless rigorously prespecified.
- Unverified Anecdotes & Preclinical Models: Insufficient under federal law to overturn Phase III clinical endpoint verifications.
GRADE Evaluation & Risk of Bias
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework categorizes evidence quality into four tiers:
- HIGH Further research is very unlikely to change our confidence in the estimate of effect.
- MODERATE Further research is likely to have an important impact on confidence.
- LOW Further research is very likely to have an important impact and may change the estimate.
- VERY LOW Any estimate of effect is very uncertain.
Downgrading factors include risk of bias, inconsistency, indirectness, imprecision, and publication bias.
How does this matrix synthesize pooled effect sizes?
The tool applies inverse-variance weighting (fixed/random-effects analog) based on the supplied sample size and confidence interval widths to approximate a summary risk ratio, while grading overall evidence certainty according to study design hierarchy and peer-review integrity.
Can this matrix be used for state legislative or FDA advisory committee preparation?
Yes. The generated questions and regulatory verdicts are modeled after standard Senate HELP Committee and FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) deliberation frameworks.